Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
- PMID: 33082079
- DOI: 10.1016/j.healun.2020.09.011
Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry
Abstract
The term idiopathic pulmonary arterial hypertension (IPAH) is used to categorize patients with pre-capillary pulmonary hypertension of unknown origin. There is considerable variability in the clinical presentation of these patients. Using data from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension, we performed a cluster analysis of 841 patients with IPAH based on age, sex, diffusion capacity of the lung for carbon monoxide (DLCO; <45% vs ≥45% predicted), smoking status, and presence of comorbidities (obesity, hypertension, coronary heart disease, and diabetes mellitus). A hierarchical agglomerative clustering algorithm was performed using Ward's minimum variance method. The clusters were analyzed in terms of baseline characteristics; survival; and response to pulmonary arterial hypertension (PAH) therapy, expressed as changes from baseline to follow-up in functional class, 6-minute walking distance, cardiac biomarkers, and risk. Three clusters were identified: Cluster 1 (n = 106; 12.6%): median age 45 years, 76% females, no comorbidities, mostly never smokers, DLCO ≥45%; Cluster 2 (n = 301; 35.8%): median age 75 years, 98% females, frequent comorbidities, no smoking history, DLCO mostly ≥45%; and Cluster 3 (n = 434; 51.6%): median age 72 years, 72% males, frequent comorbidities, history of smoking, and low DLCO. Patients in Cluster 1 had a better response to PAH treatment than patients in the 2 other clusters. Survival over 5 years was 84.6% in Cluster 1, 59.2% in Cluster 2, and 42.2% in Cluster 3 (unadjusted p < 0.001 for comparison between all groups). The population of patients diagnosed with IPAH is heterogenous. This cluster analysis identified distinct phenotypes, which differed in clinical presentation, response to therapy, and survival.
Keywords: cluster; mortality; phenotypes; pulmonary arterial hypertension; survival.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Comment in
-
Multidimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping.J Heart Lung Transplant. 2021 Feb;40(2):166-167. doi: 10.1016/j.healun.2020.11.001. Epub 2020 Nov 7. J Heart Lung Transplant. 2021. PMID: 33243664 No abstract available.
-
Response to Badagliacca et al: Multi-dimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping.J Heart Lung Transplant. 2021 Feb;40(2):167-168. doi: 10.1016/j.healun.2020.11.006. Epub 2020 Nov 15. J Heart Lung Transplant. 2021. PMID: 33262004 No abstract available.
Similar articles
-
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.Lancet Respir Med. 2022 Oct;10(10):937-948. doi: 10.1016/S2213-2600(22)00097-2. Epub 2022 Jun 28. Lancet Respir Med. 2022. PMID: 35777416 Free PMC article.
-
Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension.Respirology. 2015 Apr;20(3):481-7. doi: 10.1111/resp.12464. Epub 2015 Jan 13. Respirology. 2015. PMID: 25583377
-
Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis.J Heart Lung Transplant. 2020 Apr;39(4):310-320. doi: 10.1016/j.healun.2019.12.012. Epub 2020 Jan 21. J Heart Lung Transplant. 2020. PMID: 32061507
-
Schistosomiasis-associated pulmonary arterial hypertension: a systematic review.Eur Respir Rev. 2020 Feb 5;29(155):190089. doi: 10.1183/16000617.0089-2019. Print 2020 Mar 31. Eur Respir Rev. 2020. PMID: 32024722 Free PMC article.
-
[Pulmonary arterial hypertension in patients with congenital heart disease: current issues and health care situation].Dtsch Med Wochenschr. 2013 Jun;138(23):1247-52. doi: 10.1055/s-0033-1343189. Epub 2013 May 29. Dtsch Med Wochenschr. 2013. PMID: 23720182 Review. German.
Cited by
-
Pulmonary Vascular Research Institute GoDeep: A meta-registry merging deep phenotyping datafrom international PH reference centers.Pulm Circ. 2022 Jul 1;12(3):e12123. doi: 10.1002/pul2.12123. eCollection 2022 Jul. Pulm Circ. 2022. PMID: 36034404 Free PMC article.
-
Haemodynamic spectrum in heritable pulmonary arterial hypertension: a continuum from pre-capillary to combined pulmonary hypertension-case series.Eur Heart J Case Rep. 2025 Feb 26;9(3):ytaf109. doi: 10.1093/ehjcr/ytaf109. eCollection 2025 Mar. Eur Heart J Case Rep. 2025. PMID: 40103798 Free PMC article.
-
Pulmonary hypertension - the latest updates for physicians.Clin Med (Lond). 2023 Sep;23(5):449-454. doi: 10.7861/clinmed.2023-23.5.Cardio4. Clin Med (Lond). 2023. PMID: 37775164 Free PMC article. Review.
-
Lung Transplant Outcomes in Patients With Preoperative Catheterization Indicating Group 2 Pulmonary Hypertension.Pulm Circ. 2025 Jun 2;15(2):e70107. doi: 10.1002/pul2.70107. eCollection 2025 Apr. Pulm Circ. 2025. PMID: 40463492 Free PMC article.
-
Macitentan and Tadalafil Combination Therapy in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities: Real-World Evidence from OPUS and OrPHeUS.Adv Ther. 2025 Jul;42(7):3306-3333. doi: 10.1007/s12325-025-03180-0. Epub 2025 May 19. Adv Ther. 2025. PMID: 40388087 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical